Clinical trial NCT06405880: Pharmacist Case Finding and Intervention for Vascular Prevention Trial
Official title: Implementation of Pharmacist Case Finding and Intervention for Vascular Prevention (PRxOACT) Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cardiovascular Risk Factors
Blood Pressure
Cardiovascular Disease
Diabetes
Dyslipidemia
Keywords: cardiovascular
blood pressure
diabetes
dyslipidemia
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2024-05-09
Enrollment: 982
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Heart disease is a common and serious medical condition which causes nearly one in every three deaths worldwide every year.

The factors which increase people's risk for heart disease are well-known, but there needs to be more support given to people to reduce their risk of heart disease. Pharmacists are front line primary healthcare providers who see patients more frequently than any other healthcare provider and can help people reduce their risk of heart disease.

This research project aims to see whether a pharmacist-led intervention can help people reduce their risk of heart disease. The potential impact of this project is to empower people to understand how to reduce their risk of heart disease and reduce the burden of heart disease on the community.


Eligibility criteria: Inclusion Criteria:

* Adults (18 years or older)
* Clinical diagnosis of at least one of the following conditions:

  * Diabetes,
  * Chronic kidney disease,
  * Chronic inflammatory condition (e.g., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, systemic lupus erythematosus or psoriasis),
  * Atherosclerotic vascular disease,
  * Hypertension,
  * Obesity (defined as body mass index greater than 30),
  * Current tobacco or vape use

Exclusion Criteria:

* Unwilling to participate/sign consent form;
* Unwilling or unable to participate in regular follow-up visits; or
* Pregnant

Primary outcomes:
measure: Estimated cardiovascular risk
timeFrame: Up to 6 months.
Secondary outcomes:
measure: A1c in those who have diabetes
timeFrame: Up to 6 months.
measure: Blood pressure
timeFrame: Up to 6 months.
measure: LDL Cholesterol Concentration
timeFrame: Up to 6 months.
measure: Tobacco use or vaping
timeFrame: Up to 6 months.
measure: Yield of enrolment approaches
timeFrame: Up to 6 months.
measure: Yield of enrollment by pharmacy type
timeFrame: Up to 6 months.
measure: Shared-decision making uptake
timeFrame: Up to 6 months.
measure: Previous cardiovascular risk assessment
timeFrame: Up to 6 months.
measure: Proportion categorized as having high cardiovascular risk
timeFrame: Up to 6 months.
measure: Patient satisfaction
timeFrame: Up to 6 months.
measure: Types of intervention delivered by the pharmacist
timeFrame: Up to 6 months.
measure: Quality of life reported by study participants
timeFrame: Up to 6 months.
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: The University of Alberta
state: Alberta
Study officials:
affiliation: University of Alberta
name: Ross Tsuyuki
role: STUDY_DIRECTOR
affiliation: University of Alberta
name: Yazid Al Hamarneh
role: PRINCIPAL_INVESTIGATOR
References: